Nupenta-D Capsule is a combination pharmaceutical formulation containing Domperidone 10 mg and Pantoprazole 20 mg, designed for the management of gastrointestinal disorders characterized by acid reflux, dyspepsia, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcer disease. The combined action of these agents offers symptomatic relief and promotes mucosal healing. Nupenta-D is indicated for patients with symptomatic GERD accompanied by delayed gastric emptying or upper gastrointestinal motility disorders. It should be administered as prescribed by a healthcare professional, with consideration of contraindications such as hypersensitivity to either component, prolactin-dependent tumors, or concurrent use of medications that prolong the QT interval. Monitoring for adverse effects like headache, dry mouth, or abdominal cramps is recommended. This combination therapy optimizes patient outcomes by addressing both acid suppression and motility enhancement in gastrointestinal management.